The pharmaceutical giant Bayer AG has become the latest foreign drug maker to come under scrutiny for its practices in China.

The German-based company said in a statement Friday that it is cooperating with Chinese authorities in the investigation of a potential case of unfair competition after officials visited a Bayer branch office in late August. Bayer did not provide further details of the case or say where the branch office was.